Ibogaine vs Ketamine
Evidence-based comparison of two leading psychedelic-assisted therapies for mental health and addiction
The Psychedelic Renaissance: Two Different Paths
Both ibogaine and ketamine represent the forefront of psychedelic-assisted therapy, yet they serve fundamentally different purposes. Ibogaine is a powerful addiction interrupter derived from the African iboga plant, while ketamine is a dissociative anesthetic repurposed for treatment-resistant depression. Understanding their differences is critical to choosing the right treatment.
Quick Comparison
| Feature | Ibogaine | Ketamine |
|---|---|---|
| Primary Use | Opioid & stimulant addiction | Treatment-resistant depression |
| Mechanism | Multi-receptor reset (NMDA, opioid, serotonin, GDNF) | NMDA antagonism, glutamate surge, BDNF increase |
| Session Duration | 24-48 hours (single intensive session) | 45 min - 2 hours (per session) |
| Treatment Protocol | 1 session, optional boosters | 6-12 sessions over weeks/months |
| Experience | Deeply introspective, visionary, life review | Dissociative, floating, ego dissolution |
| Opioid Withdrawal | Eliminates within hours | Minimal effect |
| Legal Status (US) | Schedule I (available internationally) | Schedule III / FDA-approved (esketamine) |
| Cost | $5,000-$15,000 (complete treatment) | $400-$2,000/session ($2,400-$12,000 total) |
| Insurance | No coverage | Sometimes (especially Spravato) |
| Cardiac Risk | Moderate (QT prolongation) | Low (temporary BP elevation) |
How They Work: Different Mechanisms
Ibogaine's Multi-Receptor Reset
Ibogaine and its long-acting metabolite noribogaine affect multiple neurotransmitter systems simultaneously, making it uniquely effective for addiction:
- Opioid receptors: Resets mu, kappa, and delta receptors to a pre-addicted state, eliminating physical dependence
- NMDA receptors: Blocks glutamate excitotoxicity (similar to ketamine's mechanism)
- Serotonin system: 5-HT2A receptor agonist producing psychedelic effects and mood elevation
- Sigma receptors: Neuroprotection and anti-addiction signaling
- GDNF upregulation: Glial cell line-derived neurotrophic factor promotes neuronal healing and reduces cravings for weeks to months
Ketamine's NMDA Antagonism
Ketamine works primarily through a single but powerful mechanism:
- NMDA receptor blockade: Interrupts depressive thought loops and default mode network overactivity
- Glutamate surge: Triggers rapid synaptogenesis (new neural connections)
- BDNF increase: Brain-derived neurotrophic factor enhances neuroplasticity within hours
- Anti-inflammatory: Reduces neuroinflammation linked to depression and chronic pain
- mTOR pathway activation: Promotes dendritic spine growth, restoring synaptic connections
Effectiveness by Condition
Opioid Addiction
- Ibogaine: Highly effective. 80-95% withdrawal elimination within 24 hours. 50-65% sustained abstinence at 12 months with proper aftercare (Brown & Alper, 2018; Noller et al., 2018)
- Ketamine: Limited evidence. Not recommended for opioid detox. Some emerging research for craving reduction as adjunct therapy
Treatment-Resistant Depression
- Ibogaine: Promising but limited formal research. Anecdotal reports of significant mood improvement post-treatment. Recent MAPS-affiliated studies underway
- Ketamine: FDA-approved (esketamine/Spravato). 50-70% response rate within 24 hours. Well-established evidence base from multiple Phase III trials
PTSD & Trauma
- Ibogaine: Strong anecdotal evidence, especially for trauma co-occurring with addiction. Veterans increasingly seeking ibogaine for PTSD. Formal trials in progress
- Ketamine: Growing clinical use. Multiple studies show significant PTSD symptom reduction. Often combined with psychotherapy
Chronic Pain
- Ibogaine: Limited evidence. May help via opioid receptor modulation and neuroplasticity. Not a primary indication
- Ketamine: Well-established for neuropathic pain, fibromyalgia, CRPS, and migraine. IV ketamine infusions widely used in pain clinics
Combination Therapy
Some clinics explore sequential protocols: ibogaine first for addiction detox, followed weeks later by ketamine sessions for co-occurring depression or PTSD. These must be properly spaced (2-4 weeks apart) and medically supervised. This approach addresses both the neurochemical addiction (ibogaine) and mood/trauma disorders (ketamine).
The Treatment Experience
Ibogaine Journey (24-48 Hours)
- Hour 1-4 (Onset): Visual patterns emerge, body awareness heightens, introspection begins
- Hour 4-12 (Peak): Deep psychological material surfaces—life review, vivid visions, trauma processing
- Hour 12-24 (Integration): Gradual return, insights crystallize, rest and reflection
- Days 2-7 (Recovery): Fatigue, emotional processing, temporary ataxia resolves
- Weeks 1-4: Energy returns, clarity increases, cravings remain significantly reduced
Ketamine Session (45 min - 2 Hours)
- Minutes 0-10: Onset of dissociation, body feels distant or weightless
- Minutes 10-40: Peak effects—alternate realities, ego dissolution, expansive insights
- Minutes 40-60: Gradual return to baseline awareness
- Post-session: Often feel lighter, more hopeful, emotional relief
- Following days: Antidepressant effects build and consolidate
- Repeat: Sessions weekly to biweekly for 6-12 treatments, then maintenance
Safety & Contraindications
Ibogaine Safety Profile
- Cardiac risk: QT prolongation requires normal EKG screening. Contraindicated in cardiac disease
- Neurological: Temporary ataxia (coordination issues), rare seizures
- Liver function: Requires hepatic screening. Contraindicated in severe liver disease
- Drug interactions: Extensive list. Use the Medication Safety Checker
- Medical monitoring: Requires continuous cardiac monitoring in a clinical setting
Ketamine Safety Profile
- Cardiovascular: Temporary blood pressure and heart rate elevation. Generally lower cardiac risk than ibogaine
- Psychological: Can exacerbate psychosis or mania in susceptible individuals
- Bladder: Chronic high-dose use causes interstitial cystitis (rare in medical settings)
- Dependence: Low addiction potential in clinical settings, moderate with recreational use
- Dissociation: Can be distressing for some patients. Pre-treatment preparation important
Accessibility & Cost
Accessing Ibogaine Treatment
- Travel to Mexico, Costa Rica, Canada, or other countries where ibogaine is legal
- 1-2 week commitment (treatment + recovery period)
- Pre-treatment medical screening required weeks in advance
- Cost: $5,000-$15,000 including clinic stay, plus travel expenses
- No insurance coverage. Use the Cost Calculator for estimates
Accessing Ketamine Treatment
- Growing network of clinics in most US cities
- Sessions fit around work and daily life
- Telemedicine options available (at-home troches/lozenges)
- Spravato (esketamine nasal spray) at certified REMS clinics
- Some insurance coverage, especially for Spravato
- $400-$2,000 per session, $2,400-$12,000 for full protocol
Who Should Choose Which?
Choose Ibogaine If You:
- Have opioid or stimulant addiction as your primary concern
- Want comprehensive detox + psychological healing in one treatment
- Prefer a single intensive session over months of ongoing treatment
- Have good cardiac health (confirmed by EKG)
- Can commit to 1-2 weeks away from home and international travel
- Have tried conventional rehab without lasting success
Choose Ketamine If You:
- Struggle with treatment-resistant depression or suicidal ideation
- Have PTSD, anxiety, or chronic pain as primary concerns
- Need locally accessible treatment that fits around your schedule
- Prefer shorter, repeatable sessions with gradual improvement
- Want FDA-approved treatment with potential insurance coverage
- Have cardiac conditions that contraindicate ibogaine
- Are dealing with alcohol (but not opioid) addiction
Frequently Asked Questions
Is ibogaine or ketamine better for opioid addiction?
Ibogaine is significantly more effective for opioid addiction. It eliminates withdrawal symptoms within hours and resets opioid receptors to a pre-addicted state. Ketamine has minimal effect on opioid withdrawal and is not recommended for opioid detox. Studies show 50-65% sustained abstinence at 12 months with ibogaine plus aftercare, compared to limited evidence for ketamine in opioid use disorder.
Can you use ibogaine and ketamine together?
Some clinics explore sequential protocols: ibogaine first for addiction detox, followed weeks later by ketamine sessions for co-occurring depression or PTSD. However, they should never be used simultaneously and must be properly spaced (at least 2-4 weeks apart) under medical supervision. The combination addresses both addiction (ibogaine) and mood disorders (ketamine).
Why is ketamine legal in the US but ibogaine is not?
Ketamine was FDA-approved as an anesthetic in 1970 and later repurposed for depression (esketamine/Spravato in 2019). It has decades of clinical data. Ibogaine was placed on Schedule I in 1967 with limited research at the time. While ibogaine research is growing, the FDA approval process requires large-scale clinical trials that are only now underway. Several US states are exploring ibogaine decriminalization.
How many sessions does each treatment require?
Ibogaine typically requires a single intensive session lasting 24-48 hours, with optional booster doses months later. Ketamine requires 6-12 sessions over several weeks, each lasting 45 minutes to 2 hours, followed by maintenance sessions every few weeks to months. The total time commitment for ketamine is significantly longer.
Which treatment is safer?
Ketamine has a safer cardiovascular profile and is generally considered lower risk when administered in clinical settings. Ibogaine carries cardiac risks including QT prolongation and requires thorough cardiac screening (EKG, electrolyte panels) before treatment. However, ibogaine's single-session approach means less cumulative exposure. Both require medical supervision and proper screening.
What does ibogaine treatment cost compared to ketamine?
A complete ibogaine treatment at a specialized clinic costs $5,000-$15,000 including medical screening, the session, and recovery stay. Ketamine sessions cost $400-$2,000 each, with a typical 6-session protocol totaling $2,400-$12,000. Ketamine may be partially covered by insurance (especially Spravato), while ibogaine is never covered and requires international travel costs.
The Bottom Line
Ibogaine and ketamine are both transformative treatments, but for different conditions. Ibogaine excels at addiction interruption—particularly opioid and stimulant dependence—through its multi-receptor reset mechanism. Ketamine is the gold standard for treatment-resistant depression with FDA approval and growing accessibility. For patients with co-occurring addiction and depression, sequential treatment may offer the most comprehensive approach.
Considering ibogaine treatment? Contact us for a free consultation and pre-screening assessment to discuss your specific situation.